You searched for: curasight

Recruitment in full swing for Curasight's prostate cancer study

Curasight is making good progress in its Phase II study with the uTRACE® diagnostic platform for patients with prostate cancer. All nine...

Curasight advances with phase II study in prostate cancer

Curasight reinforces the value of uTRACE with new US patent

Curasight has further strengthened the patent protection for its diagnostic platform uTRACE® with the granting of a new US patent. The patent extension provides...

Curasight extends patent protection for uTRACE

Curasight’s eventful half-year crowned by EMA approval

It has been an eventful year so far for Curasight. The company has completed a rights issue that raised DKK 47 million,...

Curasight enters clinical trials with uTREAT in brain cancer

Curasight has received approval from the European Medicines Agency EMA to begin its first clinical study with uTREAT, a new...

Curasight receives approval for Phase I study with uTREAT

Curasight applies for clinical trial for uTREAT in brain cancer

The Danish biotechnology company Curasight has submitted an application to the EMA for a clinical trial authorization for a phase...

Curasight submits application for Phase I study with uTREAT

Curasight CEO: “We will deliver important milestones in the next 12 months”

Curasight is working with the goal of transforming cancer care through its uPAR-based theranostics platform. Following an IPO in which it raised 47...

The subscription period for Curasight's rights issue has begun.

Curasight is currently conducting a rights issue of DKK 100 million and the subscription period ends on May 16. After...

Curasight strengthens investor base with Curium and Pentwater

Curasight has announced a rights issue with the aim of raising approximately DKK 100 million. The company has already secured approximately...